(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Clinical trial NCT03580655 · COMPLETED

Trial details

NCT number: NCT03580655
Sponsor: Blueprint Medicines Corporation
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Systemic Mastocytosis Aggressive Systemic Mastocytosis Systemic Mastocytosis With an Associated Hematologic Neoplasm Mast Cell Leukemia

Start date: 2018-11-21
Primary completion: 2024-12-18
Enrollment: 107

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.